Thermo Fisher’s COVID-19 Test Could Have Inaccurate Results

FDA warned earlier this week that Thermo Fisher Scientific’s TaqPath test could have a risk of false results. This follows the Waltham, MA-based company exiting its bid to acquire Qiagen for $12.5 billion.

Source: Thermo Fisher’s COVID-19 Test Could Have Inaccurate Results